Travere Therapeutics' Invested Capital rose 92.85% to $73.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.6 million, marking a year-over-year increase of 92.85%. This contributed to the annual value of $127.8 million for FY2024, which is 36.38% down from last year.
Travere Therapeutics' Invested Capital amounted to $73.6 million in Q3 2025, which was down 27.58% from $101.6 million recorded in Q2 2025.
In the past 5 years, Travere Therapeutics' Invested Capital ranged from a high of $362.7 million in Q1 2021 and a low of $15.1 million during Q2 2024.
For the 3-year period, Travere Therapeutics' Invested Capital averaged around $121.1 million, with its median value being $101.6 million (2025).
In the last 5 years, Travere Therapeutics' Invested Capital crashed by 87.72% in 2024 and then spiked by 570.66% in 2025.
Quarterly analysis of 5 years shows Travere Therapeutics' Invested Capital stood at $309.5 million in 2021, then crashed by 83.89% to $49.9 million in 2022, then surged by 302.82% to $200.8 million in 2023, then plummeted by 36.38% to $127.8 million in 2024, then skyrocketed by 92.85% to $73.6 million in 2025.
Its Invested Capital stands at $73.6 million for Q3 2025, versus $101.6 million for Q2 2025 and $101.6 million for Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value